SG11201806161TA - Antibodies for il-17c - Google Patents
Antibodies for il-17cInfo
- Publication number
- SG11201806161TA SG11201806161TA SG11201806161TA SG11201806161TA SG11201806161TA SG 11201806161T A SG11201806161T A SG 11201806161TA SG 11201806161T A SG11201806161T A SG 11201806161TA SG 11201806161T A SG11201806161T A SG 11201806161TA SG 11201806161T A SG11201806161T A SG 11201806161TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- february
- pct
- antibodies
- rule
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 3
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156582 | 2016-02-19 | ||
| EP16156651 | 2016-02-22 | ||
| PCT/EP2017/053592 WO2017140831A1 (en) | 2016-02-19 | 2017-02-17 | Antibodies for il-17c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806161TA true SG11201806161TA (en) | 2018-08-30 |
Family
ID=58057136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806161TA SG11201806161TA (en) | 2016-02-19 | 2017-02-17 | Antibodies for il-17c |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20190048071A1 (hu) |
| EP (1) | EP3416983B1 (hu) |
| JP (2) | JP6535139B2 (hu) |
| KR (1) | KR102715157B1 (hu) |
| CN (1) | CN108699143B (hu) |
| AU (1) | AU2017219837B2 (hu) |
| BR (1) | BR112018016798A2 (hu) |
| CA (1) | CA3014842A1 (hu) |
| CL (1) | CL2018002340A1 (hu) |
| CO (1) | CO2018008724A2 (hu) |
| CU (1) | CU20180087A7 (hu) |
| CY (1) | CY1124296T1 (hu) |
| DK (1) | DK3416983T3 (hu) |
| EA (1) | EA037813B1 (hu) |
| EC (1) | ECSP18070641A (hu) |
| ES (1) | ES2877376T3 (hu) |
| HR (1) | HRP20211059T1 (hu) |
| HU (1) | HUE054755T2 (hu) |
| IL (1) | IL260733B2 (hu) |
| LT (1) | LT3416983T (hu) |
| MA (2) | MA44227B1 (hu) |
| MD (1) | MD3416983T2 (hu) |
| MX (1) | MX2018009860A (hu) |
| PH (1) | PH12018501739A1 (hu) |
| PL (1) | PL3416983T3 (hu) |
| RS (1) | RS62012B1 (hu) |
| SG (1) | SG11201806161TA (hu) |
| SI (1) | SI3416983T1 (hu) |
| TN (1) | TN2018000289A1 (hu) |
| TW (1) | TW201734041A (hu) |
| WO (1) | WO2017140831A1 (hu) |
| ZA (1) | ZA201806249B (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180058806A (ko) * | 2015-10-05 | 2018-06-01 | 모르포시스 아게 | 아토피 피부염의 치료 및/또는 예방을 위한 il-17c의 길항제 |
| CN108699143B (zh) | 2016-02-19 | 2021-11-09 | 莫佛塞斯公司 | Il-17c的抗体 |
| EP3688031A1 (en) | 2017-09-25 | 2020-08-05 | MorphoSys AG | Treatment of atopic dermatitis |
| GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
| TW202011995A (zh) * | 2018-07-03 | 2020-04-01 | 比利時商葛萊伯格有限公司 | 高濃度液體抗體配製物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK0985039T3 (da) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
| DK1076703T4 (da) * | 1998-05-15 | 2011-03-28 | Genentech Inc | Terapeutiske anvendelser af IL-17-homologe polypeptider |
| IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| AU2005295421A1 (en) | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation |
| WO2007047738A1 (en) * | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| CA2666842A1 (en) | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| EP2633317A1 (en) * | 2010-10-25 | 2013-09-04 | Genentech, Inc. | Treatment of gastrointestinal inflammation and psoriasis a |
| ES2696548T3 (es) | 2010-11-19 | 2019-01-16 | Morphosys Ag | Una colección de secuencias de anticuerpos y su uso |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| CN103974976A (zh) * | 2011-10-19 | 2014-08-06 | 莫佛塞斯公司 | 用于治疗炎性病症的il17c拮抗剂 |
| WO2013186236A1 (en) | 2012-06-12 | 2013-12-19 | Orega Biotech | Antagonists of il-17 isoforms and their uses |
| DK3233915T3 (da) * | 2014-12-15 | 2024-09-30 | Morphosys Ag | Antistoffer til il-17c |
| CN108699143B (zh) * | 2016-02-19 | 2021-11-09 | 莫佛塞斯公司 | Il-17c的抗体 |
-
2017
- 2017-02-17 CN CN201780011965.2A patent/CN108699143B/zh active Active
- 2017-02-17 TN TNP/2018/000289A patent/TN2018000289A1/en unknown
- 2017-02-17 KR KR1020187024953A patent/KR102715157B1/ko not_active Application Discontinuation
- 2017-02-17 SG SG11201806161TA patent/SG11201806161TA/en unknown
- 2017-02-17 RS RS20210775A patent/RS62012B1/sr unknown
- 2017-02-17 HU HUE17705873A patent/HUE054755T2/hu unknown
- 2017-02-17 MA MA44227A patent/MA44227B1/fr unknown
- 2017-02-17 SI SI201730777T patent/SI3416983T1/sl unknown
- 2017-02-17 ES ES17705873T patent/ES2877376T3/es active Active
- 2017-02-17 CA CA3014842A patent/CA3014842A1/en active Pending
- 2017-02-17 JP JP2018543220A patent/JP6535139B2/ja active Active
- 2017-02-17 CU CU2018000087A patent/CU20180087A7/es unknown
- 2017-02-17 DK DK17705873.2T patent/DK3416983T3/da active
- 2017-02-17 EP EP17705873.2A patent/EP3416983B1/en active Active
- 2017-02-17 BR BR112018016798A patent/BR112018016798A2/pt unknown
- 2017-02-17 AU AU2017219837A patent/AU2017219837B2/en active Active
- 2017-02-17 MA MA43088A patent/MA43088B1/fr unknown
- 2017-02-17 WO PCT/EP2017/053592 patent/WO2017140831A1/en active Application Filing
- 2017-02-17 LT LTEP17705873.2T patent/LT3416983T/lt unknown
- 2017-02-17 EA EA201891594A patent/EA037813B1/ru unknown
- 2017-02-17 US US16/076,401 patent/US20190048071A1/en not_active Abandoned
- 2017-02-17 MD MDE20190007T patent/MD3416983T2/ro unknown
- 2017-02-17 IL IL260733A patent/IL260733B2/en unknown
- 2017-02-17 PL PL17705873T patent/PL3416983T3/pl unknown
- 2017-02-17 TW TW106105384A patent/TW201734041A/zh unknown
- 2017-02-17 MX MX2018009860A patent/MX2018009860A/es unknown
-
2018
- 2018-08-08 US US16/058,143 patent/US10259869B2/en active Active
- 2018-08-16 PH PH12018501739A patent/PH12018501739A1/en unknown
- 2018-08-16 CL CL2018002340A patent/CL2018002340A1/es unknown
- 2018-08-21 CO CONC2018/0008724A patent/CO2018008724A2/es unknown
- 2018-09-17 ZA ZA2018/06249A patent/ZA201806249B/en unknown
- 2018-09-19 EC ECSENADI201870641A patent/ECSP18070641A/es unknown
-
2019
- 2019-02-26 US US16/286,231 patent/US10633439B2/en active Active
- 2019-04-26 JP JP2019086144A patent/JP6916834B2/ja active Active
-
2020
- 2020-03-18 US US16/822,844 patent/US11987621B2/en active Active
-
2021
- 2021-07-02 HR HRP20211059TT patent/HRP20211059T1/hr unknown
- 2021-07-06 CY CY20211100604T patent/CY1124296T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201806161TA (en) | Antibodies for il-17c | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |